Table 2.

Plasma cytokine levels in carrageenan-inflamed rats

	Veh + sham	Veh + Carr	Dic + Carr	Cmpd B + Carr
TNF-α	<LOD	9.1 ± 3.6	2.7 ± 2.7	<LOD
IL-1α	73.4 ± 3.9	83.2 ± 5.5	79.5 ± 6.1	76.1 ± 0.5
IL1-β	<LOD	<LOD	<LOD	<LOD
IL-2	462.7 ± 15.9	414.9 ± 57.4	452.4 ± 56.5	467.9 ± 107
IL-4	<LOD	<LOD	<LOD	<LOD
IL-6	36.2 ± 0.7	44.1 ± 6.5	37.1 ± 8.8	40.9 ± 12.5
IL-10	<LOD	<LOD	<LOD	<LOD
IL-12	928.4 ± 186.2	751.6 ± 149.3	969.7 ± 164.7	703.2 ± 144.6
INF-γ	<LOD	<LOD	<LOD	<LOD
GM-CSF	<LOD	<LOD	<LOD	<LOD

The rats were administered either diclofenac (Dic; 10 mg·kg⁻¹, p.o., t =−120 min), compound B (Cmpd B; 30 mg·kg⁻¹, s.c., t =−30 min) or vehicle (Veh, 15% MBCD) at the time (t) indicated before the injection of either carrageenan (Carr) or vehicle (sham) in the hind paw. Terminal plasma samples were collected at 2 h post-carrageenan treatment (n= 4 per group) and cytokine levels (pg·mL⁻¹) measured. The lower detection limits for the individual cytokines were as follows: TNF-α (1.7 pg·mL⁻¹), IL-1α (43.4 pg·mL⁻¹), IL-1β (23.1 pg·mL⁻¹), IL-2 (46.6 pg·mL⁻¹), IL-4 (2.8 pg·mL⁻¹), IL-6 (11.4 pg·mL⁻¹), IL-10 (49.8 pg·mL⁻¹), IL-12 (14.2 pg·mL⁻¹), INF-γ (5.8 pg·mL⁻¹), GM-CSF (7.3 pg·mL⁻¹).